“We are excited to announce the initiation of the Phase 1b study in which NXP800 will be tested, for the first time, in patients with a target disease,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. “The robust preclinical anti-tumor activity of NXP800, coupled with the data from the Phase 1a dose escalation study, led to the design of the Phase 1b study, including the definition of the patient population and selection of doses and dosing schedules.” Mr. Bentsur concluded, “Based on the totality of the data generated to date, we believe that NXP800 has the potential to become an effective treatment for patients with platinum-resistant, ARID1a-mutated ovarian carcinoma, as well as additional target tumor types, which we plan to also investigate in the near term.”
